REFERENCES
1. Saito, Y., C. S. Boddupalli, C. Borsotti, and M. G. Manz. 2013. Dendritic cell homeostasis is maintained by nonhematopoietic and T-cell-produced Flt3-ligand in steady state and during immune responses.Eur. J. Immunol. 43: 1651–1658.
2. Zhang, S., C. Mantel, and H. E. Broxmeyer. 1999. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J. Leukoc. Biol. 65: 372–380.
3. Sathaliyawala, T., W. E. O’Gorman, M. Greter, M. Bogunovic, V. Konjufca, Z. E. Hou, G. P. Nolan, M. J. Miller, M. Merad, and B. Reizis. 2010. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 33: 597–606.
4. Laouar, Y., T. Welte, X. Y. Fu, and R. A. Flavell. 2003. STAT3 Is Required for Flt3L-Dependent Dendritic Cell Differentiation.Immunity 19: 903–912.
5. Onai, N., A. Obata-Onai, R. Tussiwand, A. Lanzavecchia, and M. G. Manz. 2006. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon–producing and dendritic cell development. J. Exp. Med. 203: 227–238.
6. Maraskovsky, E., K. Brasel, M. Teepe, E. R. Roux, S. D. Lyman, K. Shortman, and H. J. McKenna. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med.184: 1953–1962.
7. Waskow, C., K. Liu, G. Darrasse-Jèze, P. Guermonprez, F. Ginhoux, M. Merad, T. Shengelia, K. Yao, and M. Nussenzweig. 2008. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9: 676–683.
8. Maraskovsky, E., E. Daro, E. Roux, M. Teepe, C. R. Maliszewski, J. Hoek, D. Caron, M. E. Lebsack, and H. J. McKenna. 2000. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood96: 878–884.
9. Pulendran, B., J. Banchereau, S. Burkeholder, E. Kraus, E. Guinet, C. Chalouni, D. Caron, C. Maliszewski, J. Davoust, J. Fay, and K. Palucka. 2000. Flt3-Ligand and Granulocyte Colony-Stimulating Factor Mobilize Distinct Human Dendritic Cell Subsets In Vivo. J. Immunol. 165: 566–572.
10. Mackarehtschian, K., J. D. Hardin, K. A. Moore, S. Boast, S. P. Goff, and I. R. Lemischka. 1995. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors.Immunity 3: 147–161.
11. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, E. R. Roux, M. Teepe, S. D. Lyman, and J. J. Peschon. 2000. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489–3497.
12. Ginhoux, F., K. Liu, J. Helft, M. Bogunovic, M. Greter, D. Hashimoto, J. Price, N. Yin, J. Bromberg, S. A. Lira, E. R. Stanley, M. Nussenzweig, and M. Merad. 2009. The origin and development of nonlymphoid tissue CD103+ DCs. J. Exp. Med. 206: 3115–3130.
13. Lyman, S. D., M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal, J. C. Schultz, N. T. Shahidi, S. D. Lyman, M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal, J. C. Schultz, N. T. Shahidi, B. S. D. Lyman, M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal, J. C. Schultz, N. T. Shahidi, S. D. Lyman, M. Seaberg, R. Hanna, J. Zappone, K. Brasel, J. L. Abkowitz, J. T. Prchal, J. C. Schultz, and N. T. Shahidi. 1995. Plasma/Serum Levels of flt3 Ligand Are Low in Normal Individuals and Highly Elevated in Patients With Fanconi Anemia and Acquired Aplastic Anemia. Blood 86: 4095–4096.
14. Whartenby, K. A., P. A. Calabresi, E. McCadden, B. Nguyen, D. Kardian, T. Wang, C. Mosse, D. M. Pardoll, and D. Small. 2005. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc. Natl. Acad. Sci. 102: 16741–16746.
15. Cueto, F. J., C. del Fresno, P. Brandi, A. J. Combes, E. Hernández-García, A. R. Sánchez-Paulete, M. Enamorado, C. P. Bromley, M. J. Gomez, R. Conde-Garrosa, S. Mañes, S. Zelenay, I. Melero, S. Iborra, M. F. Krummel, and D. Sancho. 2021. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J. Immunother. Cancer 9: e002054.
16. Wilson, K. R., J. A. Villadangos, and J. D. Mintern. 2021. Dendritic cell Flt3 – regulation, roles and repercussions for immunotherapy.Immunol. Cell Biol. imcb.12484.
17. Hayakawa, F., M. Towatari, H. Kiyoi, M. Tanimoto, T. Kitamura, H. Saito, and T. Naoe. 2000. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19: 624–631.
18. Mizuki, M., R. Fenski, H. Halfter, I. Matsumura, R. Schmidt, C. Muller, W. Gruning, K. Kratz-Albers, S. Serve, C. Steur, T. Buchner, J. Kienast, Y. Kanakura, W. E. Berdel, H. Serve, C. Müller, W. Grüning, K. Kratz-Albers, S. Serve, C. Steur, T. Büchner, J. Kienast, Y. Kanakura, W. E. Berdel, and H. Serve. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96: 3907–3914.
19. Kiyoi, H., R. Ohno, R. Ueda, H. Saito, and T. Naoe. 2002. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21: 2555–2563.
20. Choudhary, C., J. Schwäble, C. Brandts, L. Tickenbrock, B. Sargin, T. Kindler, T. Fischer, W. E. Berdel, C. Müller-Tidow, and H. Serve. 2005. AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. Blood106: 265–273.
21. Lee, B. H., Z. Tothova, R. L. Levine, K. Anderson, N. Buza-Vidas, D. E. E. Cullen, E. P. McDowell, J. Adelsperger, S. Fröhling, B. J. P. P. Huntly, M. Beran, S. E. Jacobsen, and D. G. Gilliland. 2007. FLT3 Mutations Confer Enhanced Proliferation and Survival Properties to Multipotent Progenitors in a Murine Model of Chronic Myelomonocytic Leukemia. Cancer Cell 12: 367–380.
22. Nagel, G., D. Weber, E. Fromm, S. Erhardt, M. Lübbert, W. Fiedler, T. Kindler, J. Krauter, P. Brossart, A. Kündgen, H. R. Salih, J. Westermann, G. Wulf, B. Hertenstein, M. Wattad, K. Götze, D. Kraemer, T. Heinicke, M. Girschikofsky, H. G. Derigs, H. A. Horst, C. Rudolph, M. Heuser, G. Göhring, V. Teleanu, L. Bullinger, F. Thol, V. I. Gaidzik, P. Paschka, K. Döhner, A. Ganser, H. Döhner, and R. F. Schlenk. 2017. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann. Hematol. 96: 1993–2003.
23. Yokota, S., H. Kiyoi, M. Nakao, T. Iwai, S. Misawa, T. Okuda, Y. Sonoda, T. Abe, K. Kahsima, Y. Matsuo, and T. Naoe. 1997. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11: 1605–1609.
24. Papaemmanuil, E., M. Gerstung, L. Bullinger, V. I. Gaidzik, P. Paschka, N. D. Roberts, N. E. Potter, M. Heuser, F. Thol, N. Bolli, G. Gundem, P. Van Loo, I. Martincorena, P. Ganly, L. Mudie, S. McLaren, S. O’Meara, K. Raine, D. R. Jones, J. W. Teague, A. P. Butler, M. F. Greaves, A. Ganser, K. Döhner, R. F. Schlenk, H. Döhner, P. J. Campbell, S. O’Meara, K. Raine, D. R. Jones, J. W. Teague, A. P. Butler, M. F. Greaves, A. Ganser, K. Döhner, R. F. Schlenk, H. Döhner, and P. J. Campbell. 2016. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374: 2209–2221.
25. Lau, C. M., S. A. Nish, N. Yogev, A. Waisman, S. L. Reiner, and B. Reizis. 2016. Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J. Exp. Med. 213: 415–431.
26. Bar-On, L., T. Birnberg, K. L. Lewis, B. T. Edelson, D. Bruder, K. Hildner, J. Buer, K. M. Murphy, B. Reizis, and S. Jung. 2010. CX3CR1+ CD8 + dendritic cells are a steady-state population related to plasmacytoid dendritic cells. Proc. Natl. Acad. Sci. 107: 14745–14750.
27. Caminschi, I., D. Vremec, F. Ahmet, M. H. Lahoud, J. A. Villadangos, K. M. Murphy, W. R. Heath, and K. Shortman. 2012. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3-/-mice.Mol. Immunol. 50: 9–17.
28. Villani, A.-C., R. Satija, G. Reynolds, S. Sarkizova, K. Shekhar, J. Fletcher, M. Griesbeck, A. Butler, S. Zheng, S. Lazo, L. Jardine, D. Dixon, E. Stephenson, E. Nilsson, I. Grundberg, D. McDonald, A. Filby, W. Li, P. L. De Jager, O. Rozenblatt-Rosen, A. A. Lane, M. Haniffa, A. Regev, and N. Hacohen. 2017. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science (80-. ). 356.
29. See, P., C.-A. Dutertre, J. Chen, P. Günther, N. McGovern, S. E. Irac, M. Gunawan, M. Beyer, K. Händler, K. Duan, H. R. Bin Sumatoh, N. Ruffin, M. Jouve, E. Gea-Mallorquí, R. C. M. Hennekam, T. Lim, C. C. Yip, M. Wen, B. Malleret, I. Low, N. B. Shadan, C. F. S. Fen, A. Tay, J. Lum, F. Zolezzi, A. Larbi, M. Poidinger, J. K. Y. Chan, Q. Chen, L. Rénia, M. Haniffa, P. Benaroch, A. Schlitzer, J. L. Schultze, E. W. Newell, and F. Ginhoux. 2017. Mapping the human DC lineage through the integration of high-dimensional techniques. Science (80-. ). 356.
30. Leylek, R., M. Alcántara-Hernández, Z. Lanzar, A. Lüdtke, O. A. Perez, B. Reizis, and J. Idoyaga. 2019. Integrated Cross-Species Analysis Identifies a Conserved Transitional Dendritic Cell Population.Cell Rep. 29: 3736–3750.e8.
31. Miller, J. C., B. D. Brown, T. Shay, E. L. Gautier, V. Jojic, A. Cohain, G. Pandey, M. Leboeuf, K. G. Elpek, J. Helft, D. Hashimoto, A. Chow, J. Price, M. Greter, M. Bogunovic, A. Bellemare-Pelletier, P. S. Frenette, G. J. Randolph, S. J. Turley, M. Merad, C. Jakubzick, A. J. Best, J. Knell, A. Goldrath, D. Koller, N. Cohen, P. Brennan, M. Brenner, A. Regev, A. Fletcher, D. Malhotra, R. Jianu, D. Laidlaw, J. Collins, K. Narayan, K. Sylvia, J. Kang, R. Gazit, D. J. Rossi, F. Kim, T. N. Rao, A. Wagers, S. A. Shinton, R. R. Hardy, P. Monach, N. A. Bezman, J. C. Sun, C. C. Kim, L. L. Lanier, T. Heng, T. Kreslavsky, M. Painter, J. Ericson, S. Davis, D. Mathis, and C. Benoist. 2012. Deciphering the transcriptional network of the dendritic cell lineage.Nat. Immunol. 13: 888–899.
32. Teshima, T., P. Reddy, K. P. Lowler, M. A. KuKuruga, C. Liu, K. R. Cooke, and J. L. M. M. Ferrara. 2002. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8$α$+ dendritic cells and reduces experimental acute graft-versus-host disease.Blood 99: 1825–1832.
33. O’Keeffe, M., T. C. Brodnicki, B. Fancke, D. Vremec, G. Morahan, E. Maraskovsky, R. Steptoe, L. C. Harrison, and K. Shortman. 2005. Fms-like tyrosine kinase 3 ligand administration overcomes a genetically determined dendritic cell deficiency in NOD mice and protects against diabetes development. Int. Immunol. 17: 307–314.
34. Lyman, S. D., L. James, J. Zappone, P. R. Sleath, M. P. Beckmann, and T. Bird. 1993. Characterization of the protein encoded by the flt3 (flk2) receptor-like tyrosine kinase gene. Oncogene 8: 815–822.
35. Schmidt-Arras, D.-E., A. Böhmer, B. Markova, C. Choudhary, H. Serve, and F.-D. Böhmer. 2005. Tyrosine Phosphorylation Regulates Maturation of Receptor Tyrosine Kinases. Mol. Cell. Biol. 25: 3690–3703.
36. Hochrein, H., M. O’Keeffe, T. Luft, S. Vandenabeele, R. J. Grumont, E. Maraskovsky, and K. Shortman. 2000. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J. Exp. Med. 192: 823–833.
37. Schnorrer, P., G. M. N. N. N. Behrens, N. S. Wilson, J. L. Pooley, C. M. Smith, D. El-Sukkari, G. Davey, F. Kupresanin, M. Li, E. Maraskovsky, G. T. Belz, F. R. Carbone, K. Shortman, W. R. Heath, and J. A. Villadangos. 2006. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc. Natl. Acad. Sci. U. S. A. 103: 10729–10734.
38. Theisen, D. J., J. T. Davidson, C. G. Briseño, M. Gargaro, E. J. Lauron, Q. Wang, P. Desai, V. Durai, P. Bagadia, J. R. Brickner, W. L. Beatty, H. W. Virgin, W. E. Gillanders, N. Mosammaparast, M. S. Diamond, L. D. Sibley, W. Yokoyama, R. D. Schreiber, T. L. Murphy, and K. M. Murphy. 2018. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science (80-. ). 362: 694–699.
39. Kingston, D., M. A. Schmid, N. Onai, A. Obata-Onai, D. Baumjohann, M. G. Manz, G. Markus, W. Dc, and M. G. Manz. 2009. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis.Blood 114: 835–843.
40. Eidenschenk, C., K. Crozat, P. Krebs, R. Arens, D. Popkin, C. N. Arnold, A. L. Blasius, C. a Benedict, E. M. Y. Moresco, Y. Xia, and B. Beutler. 2010. Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells. Proc. Natl. Acad. Sci. U. S. A. 107: 9759–9764.
41. Heydt, Q., C. Larrue, E. Saland, S. Bertoli, J. E. Sarry, A. Besson, S. Manenti, C. Joffre, and V. Mansat-De Mas. 2018. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia. Oncogene37: 787–797.
42. Roche, P. A., and K. Furuta. 2015. The ins and outs of MHC class II-mediated antigen processing and presentation. Nat. Rev. Immunol. 15: 203–216.
43. Mintern, J. D., C. Macri, W. J. Chin, S. E. Panozza, E. Segura, N. L. Patterson, P. Zeller, D. Bourges, S. Bedoui, P. J. Mcmillan, A. Idris, C. J. Nowell, A. Brown, K. J. Radford, A. P. R. R. Johnston, and J. A. Villadangos. 2015. Differential use of autophagy by primary dendritic cells specialized in cross-presentation. Autophagy 11: 906–917.
44. Mintern, J. D., and J. A. Villadangos. 2012. Autophagy and mechanisms of effective immunity. Front. Immunol. 3: 1–9.
45. Leylek, R., M. Alcántara-Hernández, Z. Lanzar, A. Lüdtke, O. A. Perez, B. Reizis, and J. Idoyaga. 2019. Integrated Cross-Species Analysis Identifies a Conserved Transitional Dendritic Cell Population.Cell Rep. 29: 3736-3750.e8.
46. Lahoud, M. H., F. Ahmet, J. G. J.-G. Zhang, S. Meuter, A. N. Policheni, S. Kitsoulis, C.-N. C. N. Lee, M. O’Keeffe, L. C. Sullivan, A. G. Brooks, R. Berry, J. Rossjohn, J. D. Mintern, J. Vega-Ramos, J. A. Villadangos, N. A. Nicola, M. C. Nussenzweig, K. J. Stacey, K. Shortman, W. R. Heath, and I. Caminschi. 2012. DEC-205 is a cell surface receptor for CpG oligonucleotides. Proc. Natl. Acad. Sci. 109: 16270–16275.
47. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA- based α- and β-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34–40.
48. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17–27.
49. Köntgen, F., G. Süss, C. Stewart, M. Steinmetz, and H. Bluethmann. 1993. Targeted disruption of the MHC class II Aa gene in C57BL/6 mice.Int. Immunol. 5: 957–964.
50. Vremec, D. 2010. The isolation of mouse dendritic cells from lymphoid tissues and the identification of dendritic cell subtypes by mutliparameter flow cytometry. Methods Mol. Biol. 595: 205–209.